

ELECTRON PARAMAGNETIC RESONANCE SPECTROSCOPIC STUDIES
OF INTESTINAL HOMOGENATES FROM NSAIDs TREATED RATS

S. Somasundaram, S. Rafi, J. K. Shergill, J. Wrigglesworth and
I. Bjarnason

Departments of Digestive Diseases, Kings College Hospital School of
Medicine, London SE5 9PJ, U.K. and , Centre for the Study of Metals In
Biology and Medicine, , King's College, University of London, Road, W8 7AH,
U.K.

Address correspondence to: Dr. S. Somasundaram, Lineberger
Comprehensive Cancer Center, CB# 7295, University of North Carolina,
Chapel Hill. N.C 27599.

Fax: 929 966 8212

Email: sivasoma@med.unc.edu

Abbreviations: EPR, electron paramagnetic resonance; NSAIDs,
nonsteroidal antiinflammatory drugs; DAHP, 2,4 diamino hydroxy pyrimidine;
DMSO, dimethyl sulfoxide

ABSTRACT:

Background and Aim:

It has been suggested that one aspect of non-steroidal anti-inflammatory drugs induced intestinal damage is due to either uncoupling of mitochondrial oxidative phosphorylation or inhibition of electron transport. We investigated the latter possibility using electron paramagnetic resonance spectroscopy.

Methods:

Electron paramagnetic resonance signals were assessed with reference to Centre 3 of Complex II in mitochondrial function following indomethacin 20 mg/kg alone and pre-treated with an inhibitor of inducible nitric oxide synthase, 2,4 diamino hydroxy pyrimidine 1.0 g/kg and nabumetone 500 mg/kg along with intestinal permeability measurement and ulcer count.

Results: Electron paramagnetic studies of NSAIDS on sub-mitochondrial particles revealed that indomethacin but not with nabumetone bound to a site near to Complex I and ubiquinone to generate a radical species. Normal rats exhibited prominent [3Fe-4S]ox signals ($g \sim 2.01$) at 20 K. One hour after indomethacin there was a prominent, intense and broad absorption pattern at ($g \sim 2.07$) suggesting appearance of radical species overlapping [3Fe-4S]ox and was unaffected by pretreatment with 2,4 diamino hydroxy pyrimidine. At 24 hrs, when macroscopic ulcers were seen, there was a new signal due to a nitric oxide radical ($\text{NO}\cdot$). In contrast, nabumetone and 2,4 diamino hydroxy pyrimidine pre-treated animals receiving indomethacin exhibited electron paramagnetic resonance spectra identical to those of controls at 24 hrs and neither was associated with small intestinal ulcers. Indomethacin and 2,4 diamino hydroxy pyrimidine pre-treated rats, but not nabumetone, had increased intestinal permeability.

Conclusion: The results suggest that the *invivo* effects of indomethacin modulates the mitochondrial respiratory chain directly at 1 h and 24 h through formation of nitric oxide. $\text{NO}\cdot$ appears to play an important role in the

late pathogenic stages of NSAID enteropathy and may be the site for targeted treatment to reduce their toxicity.

INTRODUCTION

The major problem with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) is the high prevalence of their gastrointestinal toxicity (1). Accordingly 40% of patients have non-ulcer gastric lesions, 10-25% gastric ulcer and 65% NSAID enteropathy (2). The development of safer NSAIDs is dependent on knowledge of the pathogenesis of damage. In general, two distinct phases (topical and systemic) are suggested to be involved in the pathogenesis of enteropathy (3-5). The topical phase of damage may be due to the effect of NSAIDs to uncouple mitochondrial oxidative phosphorylation or inhibit electron transfer (4-6) either of which would result in a decrease in cellular ATP levels(7) and a disrupted intestinal barrier function.

Consequently, it is suggested, increased intestinal permeability transforms the cellular damage into a tissue reaction where inflammation and ulcers occur because of mucosal exposure of luminal aggressive factors (such as acid, pepsin, bile, pancreatic secretions and bacteria) and the effects of decreased mucosal prostaglandins on the microvasculature.

In respect of early pathogenic events in the development of NSAID damage it has been shown that uncoupling of oxidative phosphorylation and inhibition of electron transport occurs with all commonly available acidic-NSAIDs. Our earlier studies indicate (8,9) that indomethacin, aspirin and naproxen uncouple mitochondrial oxidative phosphorylation at concentration between 30 and 500 μM and inhibit the electron transport chain at higher concentrations. The issue of inhibition of electron transport by NSAIDs in the pathogenesis of damage and its pathophysiological consequences is complicated by the fact that nitric oxide ($\text{NO}\bullet$), which plays a pathogenic role in the damage, may bind to metalloproteins $[\text{Fe-S}]$ of the respiratory chain and by itself increase intestinal permeability (10). Thus NSAIDs may inhibit

electron transport directly or indirectly by induction of nitric oxide (NO•)(11-16). The aim of the current study was to assess and discriminate between the direct and indirect effects of NSAIDs on electron transport of the rat small intestine using electron paramagnetic resonance (EPR) spectroscopy.

Principle: Intestinal mitochondrial electron transfer system plays a significant role in the pathogenesis of NSAID enteropathy. In the mitochondria electron transfer occur in the iron sulphur proteins arranged sequentially. Loss (oxidation) and gain of electrons (reduction) in this iron sulphur proteins can be visualized as a spectrum in the EPR machine. It has been hypothesized that NSAID might have an affinity towards these iron sulphur proteins and alter the redox state.

MATERIALS AND METHODS

Animals and experimental design.

Electron paramagnetic studies.

Male Sprague-Dawley rats (200-250g) were used throughout EPR studies. 12 rats received indomethacin 20 mg/kg, which is a commonly used dose to induce consistent small intestinal damage in the rat {(characterised by mitochondrial damage on electron microscopy within an hour,(17) neutrophil infiltration of mucosa on light microscopy at 3-5 hours and macroscopic lesions (ulcers) at 12-18 hours (18)} . A separate group of 12 rats received the non-acidic pro-NSAID nabumetone (500 mg/kg). The maximum human doses of indomethacin in man is 150 mg/day and 2000 mg for nabumetone so that the equivalent doses given here are at least 8 and 17 fold greater than the recommended doses for indomethacin and nabumetone, respectively and many times higher than this required for anti-inflammatory activity.

Nabumetone is unusual amongst NSAIDs in that it does not produce any small intestinal lesions in the rat, presumably because it is non-acidic (and hence not a proton translocator or an inhibitor of the electron transport chain) and its active component 6-methoxy-2-naphthylacetic acid (6-MNA) is not

subjected to excretion in bile (9,19). Incorporation of nabumetone therefore allows assessment of the systemic effects of cyclooxygenase inhibition in isolation from its topical effects.

In separate studies the inhibitor of inducible nitric oxide synthase, 2,4 diamino hydroxy pyrimidine (DAHP; a potent inhibitor of tetrahydrobiopterin synthesis which is a cofactor for the inducible nitric oxide synthase activity) 1.0 gm /kg b.w. was administered to 12 rats intra-peritoneally 1 hr before indomethacin (20 mg/kg) gavage.

Preparation of drugs: Indomethacin and nabumetone were dissolved in 10% dimethyl sulfoxide and then diluted to the final concentration of 5% and administered orally by a gastric gavage without anaesthesia. Control rats were received the same volume and concentrations of dimethylsulfoxide.

Intestinal permeability assessment:

Rats, 12 in each group, were fasted overnight and received solvent, 20 mg/kg indomethacin or nabumetone (500 mg/kg) by gavage. 12 rats received DAHP i.p. (1.0 g/kg) 1 hr before indomethacin 20 mg/kg. Rats were fed 2 hrs later and fasted the following night. Twenty hrs after NSAID administration these rats received the intestinal permeability marker ^{51}Cr - EDTA (10 μCi / rat in 0.5ml followed, by 0.5ml water) by gavage and were placed in metabolic cages. Urine was collected for 5 hrs and the samples were counted in Wallace 1842-LKB gamma counter with appropriate standard. The percentage of the orally administered radioactive chromium excreted in urine was calculated.

Morphological assessment:

20 hours after administration of these drugs rat small intestinal mucosa (n=12) was exposed by a cut through the anti- mesenteric side and laid out each group on a piece of cork for assessment of macroscopic damage.(24) The assessments were carried out by an independent person unaware of the

drug treatments. An ulcer count was made to distinguish between pointed (<5mm) and longitudinal (>5mm) ulcers.

Isolation of mitochondrial fractions.

Bovine heart mitochondria were isolated based on a modification of Schneider & Hogeboom method (1950) (20), diluted to 10 mg protein/ml and sonicated in 3 ml aliquots on ice with eight 15 sec bursts, interrupted by 15 sec intervals, at 18 amps using a microtip probe. The sonicated suspension was centrifuged at 26,000g for 10 min at 4°C. The supernatant fraction was centrifuged at 130,000g for 1 hr, and the sub mitochondrial particles pellet resuspended for EPR analysis. This experiment was repeated for three times at various intervals. It has been attempted to isolate submitochondrial fraction of jejunal mitochondria from rats. In most of the cases we could not able to achieve a good yield of submitochondrial particles. Hence we used bovine heart mitochondria to understand the basic phenomena of NSAID binding sites.

EPR spectroscopy

1 hr and 24 hr after administration of the drugs, the animals were anaesthetised (Hypnovil and Hypnorm) and underwent laparotomy. Segments of jejunum 10cm distal to the ligament of Trietz were snap frozen with liquid nitrogen and stored for a maximum of 2 weeks. Samples were thawed and homogenised in 10% (w/v) of sucrose (74 mM), mannitol (225 mM), homogenising buffer (0.25 M) containing EDTA (1 mM), 5 mg/ml BSA solution in MOPS-NaOH buffer (10 mM), pH 7.4, by 15 strokes of a tight fitting teflon pestle. 100 ul samples were placed in quartz EPR tubes (3 mm-internal diameter) and immediately frozen in liquid nitrogen. X-band EPR spectra were recorded on a Bruker ESP 300 spectrometer fitted with an Oxford Instruments ESR900 liquid helium flow cryostat at 8 K and 20 K or 30K. The effect of 10 ul of 250mM indomethacin added to 90 ul of submitochondrial particles in a quartz EPR tube and read the EPR spectra at 8K was assessed

with appropriate controls. Spectra were an average of six scans and normalised for direct comparison. The experiments were repeated for three different times with separate group of animals.

Statistics:

Data are presented as mean \pm SEM. Statistical comparison between groups were made by Mann-Whitney U test.

RESULTS

Morphology

No macroscopic changes were observed in controls or with indomethacin and nabumetone 1 hr after drug administration. At 24 hr the indomethacin-treated group exhibited severe intestinal ulceration (pointed ulcers: mean=55 \pm 10, longitudinal ulcers: mean=15 \pm 9). No ulcers were seen in controls, nabumetone or DAHP treated indomethacin gavaged rats.[Table 1]

Intestinal permeability:

Controls excreted 2.3 \pm 1.2% of the orally administered ^{51}Cr -EDTA in 5 h urine. Intestinal permeability was not significantly ($p > 0.5$) increased following nabumetone (mean 2.7 \pm 1.5%). Indomethacin treated rats and those pre-treated with DAHP (+indomethacin) had significantly increased ($p < 0.01$) intestinal permeability to ^{51}Cr -EDTA (10.5 \pm 2.5% and 11.5 \pm 1.8% respectively) [Table 1]

EPR spectroscopical study of NSAIDs on sub-mitochondrial particles :

At 8 K, the EPR spectrum of bovine heart sub mitochondrial particles administered DMSO alone (Fig.1(i)) displayed a prominent resonance at $g \sim 2.014$. This signal was only observed in the oxidized state at temperatures below 25 K, and is characteristic of the $[\text{3Fe-4S}]_{\text{ox}}$ cluster of mitochondrial Complex II Centre S3. Extra features at $g \sim 2.04$, 1.99 are present, and are assigned to interactions between ubisemiquinone radicals (23) Indomethacin but not nabumetone or DAHP added to the sub mitchondrial particles significantly decreased the intensity of the latter featurres (Fig.1(ii)) ($g \sim 2.04$

and 1.99) suggesting formation of radical species which is indicative of binding of indomethacin to and the inhibition of the respiratory chain direct to this site.

EPR spectroscopical studies of NSAIDs on rat jejunal homogenates:.

At 20 K, control rat intestinal homogenates also displayed a signal indicative of Centre S3, albeit weaker (Fig.2a). A similar signal could be detected 1 hr and 24 hr after nabumetone administration.[Fig.2b and Fig3b)] However, with indomethacin the [3Fe-4S]ox signal intensity was decreased at 1 hr, and by 24 hr the EPR spectrum of intestinal homogenates displayed a prominent new resonance centered at $g \sim 2.0$, with a peak at $g \sim 2.07$ and a triplet splitting centered at $g \sim 2.01$, indicative of nitrosyl-haem (haem-NO) formation.[Fig.2c and Fig3c]. DAHP pre treated indomethacin group significantly decreased the haem-NO intensity at 24 hr after administration [Fig.4], thereby allowing detection of the Centre S3 signal at 8 K [Fig.5]. DAHP pretreated indomethacin group displayed the similar signals at 1hr, when compared to indomethacin alone treated group [.i.e, decreased in the [3Fe-4S]ox signal at 1hr,Data not shown]. The haem-NO signal observed in Fig.3c shows a splitting of $A(14N) \sim 330$ mT [Fig.4 at 30 K]. Similar signals have been observed for the NO-adducts of type II haem proteins such as cytochrome c oxidase and haemoglobin (21)

DISCUSSION

The present results show that indomethacin treated rats and not those pretreated with DAHP exhibited small intestinal ulcers at 20 hr. There was increased intestinal permeability and an early (1hr) direct effect of indomethacin consistent with inhibition of electron transport in both groups but only the indomethacin treated group exhibited a haem-nitrosyl complex EPR signal at $g \sim 2.07$. Thus the present result suggest that the nitric oxide radical may play a role in the development of indomethacin induced ulcers. Within the current pathogenic framework (5) where it is proposed that NSAIDs affect

mitochondrial energy metabolism leading to increased intestinal permeability and where the microvascular alterations, caused by changes in prostaglandin and nitric oxide metabolism are the driving force in the development of ulcers. The involvement of nitric oxide occurs temporarily later or at a different pathophysiological step than the intestinal permeability changes. The non-acidic Pro-NSAID nabumetone caused no intestinal lesion as previously described (22) and was not associated with changes in the EPR spectra, despite being effective inhibitors of cyclooxygenase and associated with decreased mucosal prostaglandins at much smaller doses(22). These findings are consistent with previous *in vitro* and *in vivo* work showing that nabumetone itself does not alter mitochondrial energy metabolism whilst its active metabolite 6MNA does. However it would appear that as 6MNA is formed following absorption of nabumetone, over 99% of 6MNA is protein bound within the circulation and it is not excreted in bile, insufficient intestinal concentrations of 6MNA are achieved to affect enterocyte mitochondria. NSAIDs uncouple oxidative phosphorylation at 30-500 μM and inhibit mitochondrial electron transport at higher concentration *in vitro* (8) The relative importance and contribution of uncoupling and inhibition in the pathogenesis of the "topical" Phase of damage is uncertain, but either mechanism would lead to decreased cellular ATP and hence increased intestinal permeability. In this study we assessed the characteristics of NSAID modulation of electron transport *in vivo* in rats and *in vitro* in bovine heart submitochondrial particles. The EPR spectra observed at 1hr would appear to be the result of a direct effect of indomethacin on electron transport unrelated to NO', since pretreatment with DAHP did not alter the indomethacin spectra. The EPR spectra at 24 hr post indomethacin [Fig.2B (c)] indicated formation of NO' which is further substantiated by abolition of this signal when rats were pretreated with DAHP.[Fig.3]

The activity of iNOS is controlled mainly at the levels of transcription and translation and is dependent on the availability of co-factors including tetrahydrobiopterin (BH4). A recent study has demonstrated that inhibition of BH4 synthesis reduces NO• production in vivo in experimental endotoxic shock(12). The same strategy of inhibition of BH4 synthesis has been applied in this present attempt to investigate ulcer formation in indomethacin-induced intestinal ulcer. We found that injection of DAHP an inhibitor of BH4 synthesis prevented ulcer formation, although it did not alter the increased intestinal permeability induced by indomethacin. This suggests that it does not modulate the direct biochemical actions of NSAIDs but interferes at a later stage in the pathogenesis of the damage. One possibility is that DAHP suppresses NO formation in neutrophils (iNOS) which infiltrate the mucosa in response to increased intestinal permeability. At this juncture it is interesting that inspite of the increased intestinal permeability there were no ulcers seen in the DAHP treated group indicating that inhibition of inducible nitric oxide synthase (in neutrophils and macrphages) could become a targeted therapeutic approach to reduce the intestinal toxicity of NSAIDs .

Acknowledgements: The authors thank Professor. R. Cammack for providing electron paramagnetic resonance spectroscope for the above study. Dr. S.Somasundaram was supported by an unconditional grant from Smith Kline Beecham, USA. The part of this work has been presented in American Gastroenterological Association, Digestive Disease Week Meeting, 1998.

REFERENCES

1. Barrier CH, Hirschowitz BI. Current controversies in rheumatology.(1989) Controversies and management of nonsteroidal anti-inflammatory drug induced side effects on upper gastrointestinal tract. Arthritis Rheum ; 32; 926-929

2. Bjarnason I, Hayllar J, Macpherson AJ and Russel AS. (1993) Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine. *Gastroenterology* ; 104; 1832-1847
3. Whittle BJR. (1977) Mechanism underlying gastric mucosal damage induced by indomethacin and bile salt, and the actions of prostaglandins. *Br J Pharmacol*; 60; 455-460
4. Whittle BJR. (1992) Protective mechanisms of gastric mucosa. In Gustavsson S, Kumar D, Graham DY, (eds.) *The Stomach*. Churchill livingstone, Edinburgh ; 81-101
5. Somasundaram S, Hayllar J, Rafi S, Wrigglesworth J Macpherson A Bjarnason I. (1995) The biochemical basis of NSAID-induced damage to the gastrointestinal tract: A review and a hypothesis. *Scandinavian J Gastroenterology* ; 30: 289-299
6. Whitehouse MW. (1964) Biochemical properties of anti-inflammatory drugs- III. Uncoupling of oxidative phosphorylation in a connective tissue (cartilage) and liver mitochondria by salicylate analogues: relationship of structure to activity. *Biochem Pharmacol* ; 13: 319-336
7. Somasundaram S. Hayllar J and Bjarnason I. (2000) Effect of indomethacin on rat jejunal ATP, antioxidants as well as structure and function of T84 cell line. *Gastroenterology* ; 118: A248.
8. Somasundaram S, Sigthorsson G, Simpson RJ, Watts J, Jacob M, Tavares IA, Rafi S, Roseth A, Foster R, Price AB, Wrigglesworth JM, Bjarnason I. (2000) Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. *Aliment Pharmacol Ther.* ;14:639-50.
9. Somasundaram S, Rafi S, Hayllar J, Sigthorsson G, Jacob M, Price AB, Macpherson A, Mahmood T, Scott D, Wrigglesworth JM, Bjarnason I. (1997)

Mitochondrial damage: a possible mechanism of the "topical" phase of NSAID induced injury to the rat intestine. *Gut*.;41:344-53.

10. Salzman. AL (1995) Nitric Oxide in the Gut. *New Horizons*; 3; 33-45.

11. Evans SM, Laszlo F and Whittle BJR.(1996) Nonsteroidal anti-inflammatory drugs induce nitric oxide synthase and microvascular injury in rat jejunum. A role of peroxynitrite. *Gastroenterology* ; 110: A104.

12. Bune AJ, Brand MP, Heales SJR, Shergill JK Cammack R and Cook HT.(1996) Inhibition of tetrahydrobiopterin synthesis reduces invivo Nitric oxide production in experimental endotoxic shock.*Biochem. Biophys. Res.Comm.*; 220: 13-19.

13. Tepperman BL, Brown JF, Whittle BJ.(1993) Nitric oxide synthase induction and intestinal epithelial cell viability in rats. *Am. Jol. Physiology.*; 265; G214-G218.

14. Tepperman BL, Brown JF, Korolkiewicz R, et. al:(1994) Endotoxin challengepromotes neutrophil-independentnitric oxide synthase induction, injury, and cGMP formation in rat colonicepithelial cells. *Abstr. Gastroenterology* ; 106: A782.

15. Hall DM, Buettner GR, Matthes RD, and Gisolfi CV.(1994) Hyperthermia stimulates nitric oxide formation: electron paramagnetic resonance detection of NO'-heme in blood. *J. Appl. Physiol.*; 77: 548-553.

16. Cleeter MWJ, Cooper JM, Darley-USmar VM, Moncada S. and Schapira AHV.(1994) Reversible inhibition of cytochrome c oxidase, the terminal enzyme of mitochondrial respiratory chain, by nitric oxide. Implications of neurodegenerative diseases. *FEBS letters.*; 345: 50-54.

17. Hayllar J, Somasundaram S, Saratchandra P, Levi AJ and Bjarnason I.(1991) Early cellular events in the pathogenesis of NSAID enteropathy in the rat. *Gastroenterology* ; 100: A586.

18. Anthony A, Dhillon AP, Nygard G, Hudson M, Piasecki C, Strong P, Trevethik MA, Clayton NM, Jordan C.C, Pounder RE and Wakefield AJ

- (1993) Early histological features of small intestinal injury induced by indomethacin. *Aliment Pharmacol. ther.*; 7: 29-40.
19. Melarange R, Gentry C, Connel O, Blower PR, Neil C, Kelwin AS and Toseland CD.(1992) Anti-inflammatory and gastrointestinal effects of nabumetone or its metabolite, 6-methoxy-2-naphthylacetic acid (6MNA). Comparative study with indomethacin. *Dig. Dis. Sci.*; 37: 1847-1852.
20. Schneider, W.C. and Hogeboom G.H.(1950) Intracellular distribution of enzymes V. Further studies on the distribution of cytochrome c in rat liver homogenates. *J. Biol. Chem.*;183: 123-128.
21. Yonetani T, Yamamoto H, Erman JE, Leigh JS Jr and Reed GH.(1972) Electromagnetic properties of hemoproteins V. Optical and electron paramagnetic resonance characteristics of nitric oxide derivatives of metalloporphyrin-apohemoprotein complexes. *J. Biol Chem.*;247: 2447-55.
22. Davies NM, Wright MR and Jamali F.(1994) Anti-inflammatory Drug induced small intestinal permeability: The rat is a suitable model. *pharmaceutical research.*; 11: 1652-1656.
23. Ruzicka FJ, Beinert H, Schepler KL, Dunham WR and Sands RH (1975) Interaction of ubisemiquinone with a paramagnetic component in heart tissue. *Proc. Natl. Acad. Sci.*; 72: 2886-90.
24. Somasundaram S, Rafi S, Jacob M, Sigthorsson G, Mahmud T, Sherwood R, Price AB, Macpherson A, Scott D, Wrigglesworth JM, Bjarnason I.(1997) Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. *Gut.*;May;40(5):608-13.

Legends:

Table 1: The ulcerogenic and intestinal permeability (^{51}Cr -EDTA excretion) effect of DMSO (Control), indomethacin, DAHP pretreated indomethacin and nabumetone gavaged rat small intestine.

Figure 1: The EPR spectra of (i) DMSO-control and (ii) indomethacin (25 mM final concentration) treated bovine heart submitochondrial particles at 8 K.

Figure 2: The EPR spectra of rat jejunal homogenates at 20 K after 1hr oral gavage of (a) DMSO, (b) nabumetone (500mg / kg b.wt) and (c) indomethacin (20 mg/kg b.wt)


Figure 3: The EPR spectra of rat jejunal homogenates at 20 K after 24hr oral gavage of (a) DMSO, (b) nabumetone (500mg / kg b.wt) and (c) indomethacin (20 mg/kg b.wt)


Figure 4: Comparison of EPR spectra of indomethacin and DAHP pretreated indomethacin group at 30 K after 24 hr treatment.


Figure 5: Comparison of EPR spectra of indomethacin and DAHP pretreated indomethacin group at 8 K after 24 hr treatment.

Treatment	Pointed ulcers	Longitudinal ulcers	% Excretion of ⁵¹ Cr-EDTA in Urine
Control (DMSO)	0	0	2.3 ± 1.2
Indomethacin	55 ± 10	15 ± 9	*10.5 ± 2.5
DAHP pretreated indomethacin	0	0	*11.5 ± .8
Nabumetone	0	0	2.7 ± 1.5

* P<0.01







30 K

24 hr

(i) Indomethacin

$g = 2.076$

$g = 2.044$

$g = 1.984$

(i)

Indomethacin
DAHP

(ii)

Control


(iii)

A^{14N}

(i) - (ii)

280 300 320 340 360 380

Magnetic Field [mT]



8 K

24 hr

